Europe
Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Novartis is the first company to the finish line with an approved treatment for Adult-Onset Still’s Disease (AOSD), a rare autoinflammatory disease of unknown origin.
Low doses of a long-used steroid known as dexamethasone could be the solution to improving the chances of patients who become seriously ill from COVID-19 infection and require some kind of breathing assistance.
Sanofi announced plans to increase its vaccines research and production capabilities. As part of the plan it will invest $679.4 million (€610 million) to create a new production site and a research center, both in France.
The two companies will explore potential oncology treatments with emerging technology.
The approval was based on monotherapy clinical data from a trial in 105 adults with SCLC whose disease progressed after platinum-based chemotherapy.
The U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020 – if it clears the clinic.
Bit Bio’s aim is to decode “cellular identity” in order to generate every cell type of the human body.
PRESS RELEASES